RemeGen Co's gross profit for the
three
months ended in Dec. 2023 was HK$0.0 Mil. RemeGen Co's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was HK$573.4 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. RemeGen Co's gross profit for the
three
months ended in Dec. 2023 was HK$0.0 Mil. RemeGen Co's Revenue for the
three
months ended in Dec. 2023 was HK$0.0 Mil. Therefore, RemeGen Co's Gross Margin % for the quarter that ended in Dec. 2023 was N/A%.
RemeGen Co had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage
During the past 6 years, the highestGross Margin % of RemeGen Co was 95.28%. The lowest was 21.10%. And the median was 70.66%.
RemeGen Co Gross Profit Historical Data
The historical data trend for RemeGen Co's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of RemeGen Co's Gross Profit
For the Biotechnology subindustry, RemeGen Co's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RemeGen Co's Gross Profit Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RemeGen Co's Gross Profit distribution charts can be found below:
* The bar in red indicates where RemeGen Co's Gross Profit falls into.
RemeGen Co Gross Profit Calculation
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
RemeGen Co's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as
Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$573.4 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
(Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
RemeGen Co (HKSE:09995) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
RemeGen Co had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage
RemeGen Co Gross Profit Related Terms
Thank you for viewing the detailed overview of RemeGen Co's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
RemeGen was established in 2008 and listed on the Hong Kong Stock Exchange in 2020. It is a commercial stage biotech company focused on developing drugs to treat autoimmune disease, cancer, and ophthalmic disease for the China market and potentially the global market, as well. Its core assets are disitamab vedotin (RC48), a HER2-targeting antibody-drug conjugate (ADC) for treating HER2-expressing cancers, and telitacicept (RC18), a BLyS and APRIL targeting bispecific fusion protein for treating various B-cell mediated autoimmune diseases. These drugs received their first approvals in China in 2021 and are both covered on the National Reimbursement Drug List (NRDL).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:09995 has been successfully added to your 